X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DIVIS LABORATORIES VENUS REMEDIES/
DIVIS LABORATORIES
 
P/E (TTM) x -819.1 18.1 - View Chart
P/BV x 0.2 3.9 6.1% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 VENUS REMEDIES   DIVIS LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
DIVIS LABORATORIES
Mar-16
VENUS REMEDIES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2182,484 8.8%   
Low Rs82918 8.9%   
Sales per share (Unadj.) Rs365.6142.3 257.0%  
Earnings per share (Unadj.) Rs1.541.9 3.5%  
Cash flow per share (Unadj.) Rs37.946.3 81.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs382.5161.5 236.8%  
Shares outstanding (eoy) m11.44265.47 4.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.412.0 3.4%   
Avg P/E ratio x101.040.6 248.6%  
P/CF ratio (eoy) x4.036.7 10.8%  
Price / Book Value ratio x0.410.5 3.7%  
Dividend payout %023.9 0.0%   
Avg Mkt Cap Rs m1,717451,525 0.4%   
No. of employees `0001.03.7 27.5%   
Total wages/salary Rs m3243,649 8.9%   
Avg. sales/employee Rs Th4,100.710,184.4 40.3%   
Avg. wages/employee Rs Th318.0984.1 32.3%   
Avg. net profit/employee Rs Th16.72,998.5 0.6%   
INCOME DATA
Net Sales Rs m4,18337,764 11.1%  
Other income Rs m20848 2.4%   
Total revenues Rs m4,20338,612 10.9%   
Gross profit Rs m81214,138 5.7%  
Depreciation Rs m4171,182 35.3%   
Interest Rs m38023 1,637.1%   
Profit before tax Rs m3513,781 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m182,662 0.7%   
Profit after tax Rs m1711,119 0.2%  
Gross profit margin %19.437.4 51.8%  
Effective tax rate %51.619.3 266.9%   
Net profit margin %0.429.4 1.4%  
BALANCE SHEET DATA
Current assets Rs m2,77130,947 9.0%   
Current liabilities Rs m1,9315,195 37.2%   
Net working cap to sales %20.168.2 29.4%  
Current ratio x1.46.0 24.1%  
Inventory Days Days125117 107.1%  
Debtors Days Days5485 63.1%  
Net fixed assets Rs m5,32817,027 31.3%   
Share capital Rs m114531 21.5%   
"Free" reserves Rs m4,17742,341 9.9%   
Net worth Rs m4,37642,877 10.2%   
Long term debt Rs m1,9115 40,648.9%   
Total assets Rs m8,42849,684 17.0%  
Interest coverage x1.1595.0 0.2%   
Debt to equity ratio x0.40 398,265.3%  
Sales to assets ratio x0.50.8 65.3%   
Return on assets %4.722.4 21.0%  
Return on equity %0.425.9 1.5%  
Return on capital %6.632.2 20.5%  
Exports to sales %085.3 0.0%   
Imports to sales %20.522.9 89.5%   
Exports (fob) Rs mNA32,198 0.0%   
Imports (cif) Rs m8588,654 9.9%   
Fx inflow Rs m032,270 0.0%   
Fx outflow Rs m8588,775 9.8%   
Net fx Rs m-85823,496 -3.7%   
CASH FLOW
From Operations Rs m46910,379 4.5%  
From Investments Rs m29-4,135 -0.7%  
From Financial Activity Rs m-464-6,241 7.4%  
Net Cashflow Rs m353 1,045.5%  

Share Holding

Indian Promoters % 32.9 52.0 63.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.5%  
FIIs % 0.6 19.0 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.2 386.0%  
Shareholders   20,121 31,796 63.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - MERCK LTD COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS